"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
(6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection)
For administration by intravenous infusion.
Voluven® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.
Each 100 mL of the solution contains:
|Hydroxyethyl Starch 130/0.4||6 g|
|Sodium Chloride USPin Water for Injection USP||900 mg|
|pH adjusted with Sodium Hydroxide USPor Hydrochloric Acid USP|
Electrolytes (mEq/L): Sodium 154, Chloride 154. pH 4 to 5.5. Calculated osmolarity 308 mOsmol/L.
The hydroxyethyl starch contained in Voluven® (hydroxyethyl starch in sodium chloride injection) is a synthetic colloid for use in plasma volume replacement. The chemical name of hydroxyethyl starch is poly(O-2-hydroxyethyl) starch. The structural formula of hydroxyethyl starch is
R = -H,-CH2CH2OH
R1 = -H,-CH2CH2OH or glucose units
Voluven® (hydroxyethyl starch in sodium chloride injection) is packaged in 500 mL flexible plastic containers (freeflex®). Freeflex® is a flexible container made from coextruded polyolefin and is free of PVC, plasticizers, adhesives or latex (Non-DEHP, Latex-free). The freeflex® container offers an air-closed system and can be used with non-vented IV sets which prevent external air contamination. Freeflex® is collapsible and can be used in emergency cases for pressure infusion.
Last reviewed on RxList: 2/1/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Voluven Information
Report Problems to the Food and Drug Administration
Find out what women really need.